Silicon chemistry has been demonstrated to be a novel source of chemical diversity in drug design, and this field is currently being developed into a practical and commercial enterprise [1]. The carbon/silicon switch strategy (sila-substitution of known drugs) is one of the methods that are currently used for the development of silicon-based drugs (for recent publicatons, see refs 2-4). Selected examples of this approach will be presented.[1] W. Bains, R. Tacke, Curr. Opin. Drug Discovery Dev. 2003  , 6, 526-543.[2] R. Tacke et al., ChemBioChem 2007 , 8, 1688-1699.[3] R. Tacke et al., ChemMedChem 2008  , 3, 152-164.[4] R. Tacke et al., ChemMedChem 2011  , 6, 2070-2080.[5] R. Tacke et al., ChemMedChem 2012  , 7, 523-532.

Drug design based on the carbon/silicon switch strategy

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.